STX Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru (ferric maltol), a non-salt based oral therapy for patients to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, United Kingdom.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Shield Therapeutics (LON: STX)
›
Shield Therapeutics (LON: STX) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 61 employees.
The shares were at 3.050 GBp on 19 November 2026, down 55.5% over 52 weeks. Its 52-week range is 2.900 GBp to 12.50 GBp: the price is 75.6% below the high and 5.2% above the low.
Its market capitalisation is 32.76M GBP.
Shield Therapeutics reports return on equity of 117.1%, an operating margin of -6.9% and revenue up 41.6% year over year.
Its debt exceeds its cash by 16.56M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.